<SEC-DOCUMENT>0001193125-13-202832.txt : 20130507
<SEC-HEADER>0001193125-13-202832.hdr.sgml : 20130507
<ACCEPTANCE-DATETIME>20130507061047
ACCESSION NUMBER:		0001193125-13-202832
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130507
FILED AS OF DATE:		20130507
DATE AS OF CHANGE:		20130507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		13817874

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		1 - 7 WATERLOO ROAD
		CITY:			NORTH RYDE NSW
		STATE:			C3
		ZIP:			2113
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d533533d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 6-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>UNDER THE SECURITIES EXCHANGE ACT OF
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the month of May, 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Novogen Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Translation of registrant&#146;s name into English) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1-7 Waterloo
Road, Macquarie Park, NSW, Australia </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form
20-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper
of a Form 6-K if submitted solely to provide an attached annual report to security holders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Note</B>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of
a Form 6-K submission or other Commission filing on EDGAR. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant by furnishing the
information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen Limited</B> (Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrew Bursill</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Andrew Bursill</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company Secretary</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date 7 May 2013</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g533533txpg03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7&nbsp;May 2013 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ASX RELEASE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Novogen Announces New Executive Appointments </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen today announces two new executive appointments as part of its recent acceleration of its R&amp;D programs and to support an expansion of the
Company&#146;s activities into North America. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr David Brown has been appointed Chief Scientific Officer. David is a biologist who between
2000 and 2010 was responsible for the pre-clinical testing of Novogen oncology drugs including Phenoxodiol, Triphendiol, NV128, NV-143 and NV-344. In 2010, David left Novogen and joined Janssen as a Medical Advisor. He now returns to head up the
Novogen R&amp;D program. David will be based in Sydney. His role will be to oversee the pre-clinical development of the Company&#146;s drugs pipeline of CS-6 and two recently-identified lead drug candidates with a focus on melanoma and pancreatic
cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr Andrew Heaton has been appointed President and CEO of the Company&#146;s newly-established North American subsidiary, Novogen
North America Inc. This wholly-owned subsidiary has been established to service the rapidly-expanding R&amp;D and corporate activities of the Company in the US and Europe. Andrew will continue to oversee the Company&#146;s drug discovery program and
the manufacture of drug ahead of clinical testing, both activities now centered in Europe. The Company is based in New York City and will provide a means to better interact with the Company&#146;s US-based shareholders who currently represent
approximately 70% of the Company&#146;s share base, as well as the FDA and the SEC. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Novogen </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol &#145;NRT&#146;) and NASDAQ
(symbol &#145;NVGN&#146;). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on comprehensive anti-cancer activity against both cancer cells and cancer stem cells. The
Company&#146;s inaugural drug candidate is CS-6. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About CS-6 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitor cells, cancer stem cells. CS-6 shows broad
anti-proliferative and cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being
developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Further information
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contact Dr Graham Kelly, Chief Executive Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">M: (61)&nbsp;0459 200 095 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">E: <U>Graham.Kelly@novogen.com</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Please note that the Company currently is relocating offices and that the original phone numbers no longer are in use. New contact details will be
available shortly.</U> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further information is available on the Company&#146;s web site, <U>www.novogen.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g533533txpg03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g533533txpg03.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*@"6`P$1``(1`0,1`?_$`,<```$$`@,!`0``````
M``````@`!PD*`@8!`P0%"P$``00#`0$`````````````!0`$!@<!`@,("1``
M``4#`@,$`PD+!PT``````0(#!`4&!P@`$2$2"3$R$S44-C=!46'!(C,T%3AQ
M@:%"4B-C5&1E%K'A8G*"9A?PD=&BPD-3)%5&&$@Y$0`!`@0#!`@!"@0&`P$`
M```!`@,`$00%(3$&05$2!V%Q@2(R$S,T"/"1H;'!0E)B%#7Q@A4VX7(C@T06
MT6,D1O_:``P#`0`"$0,1`#\`O\:4*%I0H6E"A:4*.M4=B".^W9Q_D^]OK59D
M)](C*4E1`&_Z-L,!;R]$#65X+Z6?06;(U;9B=HA28C"+`9VK2]P:(CJAIJH%
M43'YB-WLBA)LP$`Y>=B(=NG+K"T-)<.*3`>AO%+6UE1;DJ":MA4R#M1\ML$"
M`B.N'5!;&?1&6E&86E"A:4*%I0H6E"A:4*%I0H6E"A:4*%I0H6E"A:4*.GQ!
M$=@$O#M_F#?CK&)RC0+"S))`/3&0GVV]T!VX_P"CCQWUD`[91N)'#)49`8!]
MT/N>[Q[-^.E]48F)RF)PC&Y0]S?WA';W-9`G&<=@F8\QU1$G-N7;?;Y.X^YV
M\?>'6"DE)F(Y/+4TB;@X5=!GU[(IW=5W*B[W3IZQU$9*VX:DE*?N'CQ;MC7]
M#N7"S:*N;1D+4M60\_"OEBAX3*;C19H.(MV`',S=$`3`9)15,\RL5`FXVYQE
MS%4L-X(.R/+G,G5%9H3F:S>&@/T;U.D%)GPJPQF`1%H'%#*NT68EEJ4OA9>H
M2S=*5*4Z#IFX*5"<I:H6H)_7-)5/'^(HI&ST(LIX:R8B)#%$BJ9CI*$.,4KZ
M1ZW5/E.#NDQZ$TSJ>W:HM;=RH#-"DCB&T*W030CP$0X\!V^'7"))'3SG'LY!
M$=N`#OL`CV#L;B(:VD!G'(J4!W2E1XMGX=\<F.?;Y.P"'N&]T`[=A[-:ID3(
M@QT).2!Q*ZY?9')5-P#<0WX<-P_EW^+62)&48'%DJ05NV]7R$9@/PAQ[/A_#
MI1M]<8"<P&$/DB`;<-^.X^_Q[-9EA&._D!VSP^J,BF'CS<H<=@V^YOQX]NL$
M;LX4R!-0D/EU0A-[VWWQVUJ.+$$?-"!XLOJG''/[XE#[^_QAK/6#",QM`ZQ+
M[8X%3;;80$1#L^_M[_X-(8C'!48*DI/"HR._9"$Y@`.`"(B`!L`_YNW??6BB
ML883C(XI\)E/Z(7B!RB.Y=PX"&_NCK:2Y2$N.-0ZV9JG_I@RG$"EQ.KS45E^
MH?5.,US*"IN-QZIFL*.H>9N\R<3'UU2DQ7],,9"EI.I2+*G@T(1S/+*-UA*4
MAR($,J`B*9@&'.:I;IKXJVU"`EH?>F?JR^F/4-E^'YG4/*%G6MJJBO5CC2UH
MI"E(#C;2B'"A?%Q%0`F!PQ.KZ:51!1TF<%2`CXB1TAYD5"F3,JD=(X``&34)
MM\H.`AV:E/&ARF4^TLE"A,8;H\P*2$5*$/)6)+"<1(XF6(WB6(ZH`_IRY:5I
MF;8>>NW6]-TY2,S&7;N);Y&*I5>26C%(JC9%NSCWZBDFJX<_6#PBHBN!1\,#
M``%X:96JX?K6U$CA0@D3ZHL+F;HA&@;^BT><7FU4K+W'(`D.H"P)`D899P/V
M274IKEK?E_B%A'9DN1^1,(W%:OI*4E30EK+4I@=%,_\`%4PB8BCQXT%<GI29
M5FZ:!S`F"BCC\R#"X7JL35?H[0TEYP"9)5*0VC(]$3?2W)^D7IA&M>8M<JTZ
M7J)_IN$<3U3+,)2<1/&6!WS$-;</+#JMXK08W5R)QHL-=VRL.!7]?K8Z5948
M5K0T,`_\[*+,:D\?ZR9QB(B915-`R```"HHB0#*`R_6ZE8_^BK93^G'B`4<!
MORV9P=L^A.2>MJI&G-'W&XV^^/30U^N2GRG7)$COX!(,L,9SB*CK_&H++/%O
M$//^QS\]24.QF:EM94\EZ+X<K#-JU!&7AXNHVI>8\3(T]5U-.V+A)0W(19XF
M)1,14AQMCE_>*2N05,.`H5EUC,2CYY_%MR^O6F:E-%>:9:+K0*X'"1W"DGNJ
M2K:%"93O$1;=&[J"SF#63T%'5-+NO_'V]4S$4A=R$47.>/@W[Y=.,I6Y[-`P
M^"VDJ7>NBIOE`V%>)45*?<4D@++=36I-0QYC8FY*<X\^\IM?KTM?DTM<Y.U.
MD)*=B2H@<79\C'Z*\M4<7`P$M4TL_1:PD/$OYR1D15+Z(VBXYBK(.W?C&^0=
M%%FB)^?NB4-]52ZOR@J?B2,=DH]_4##EPJ6:1D<3U0XA"`,>(K(X<M\XC*Q>
MZ@ZUP<0;BYL9$1].6EL]$UK6?^'CF*&6<R%06QIZ6""IV7>-I!0QY"J*KERF
M;-6K0H$55#D)WN8`5+J&F_IYN3XE2R[IWQ;NI>5-51Z^IN7>DP:S4+K32%ID
M`$.N)XC,B?=;&)4<ML#W;S,?JB9>QZMS,5<9[,6OL0_.Y4H:I,E:HG2597D8
M@L=-&68Q--F)Z"P?@7Y!Q3.AN(\BZH!S:&M7F[WA7G6UE*&9X$DY?-$RNW+W
MDURX=%@U]=*ZLU.V95+=(4%ME1&27,E8X2,B(W^Q74ENE3E_8#$S/>RS#'R\
MU9'*6UU=4U,JS5F[J',L=!!E"R[DRJL:_>*E\)(IEUBBY,1%7P%5$B*/F;^M
MNL3;+FWY=81A(S"NG(9]$"-2\F[34Z2>U[RPK#<]/TL_/:5+]73RVNH&)2-J
MY#:982B2F_.0=M<:K3U9>.[M0HTS1%%L`>2;TY17>O7BQ@0CH.&8%$BTI-S+
MTX(-6Y!`RB@[CRD*<Q2]=7,V^E-95$)9""<\9C)/;%0:5TQ?-97VCTY8F5U%
MWK5A*0D=Q(D"I2U?=2D'$G=$4M)9==53*9BWN-C)BG9^T=EID/2Z+G<FJNET
M:PK&'-S&93:%/TVHDI',))(0.F`IG*)1`2+*$$#ZC:+AJ&XH35T#*$TRT@@*
M49_5%YU.A>2FBGUVO7=VKZ^^-GA<:H$I*&E;N*<B1MQGT056*MX>H+/7,G+<
MY@8UVXH:"84NM/P]X[5UXI-TC+R9))LQ0I8\*].\E"2;E%8[CQ3&;E221'<I
MN8-$K<Y>2Z!<$)!G@09X?-%>Z\L_+:AMJ+CH2XU-4E:I%A]`2MOH)S^8$=,-
M[G%F/DY9S)?'+&G&.VEJ;A5C?FE*ZGF@W0J&;IMD@[HLHO7#4DG%G!LW1/%-
MESAXB9C'6`I0$-Q'7.Y7"YT]Q126]KS>,&9G+AE*7VP9Y><O=(Z@T?=M5ZNK
MJNBIK:ZR@!EHN\7F$`\1&1$\`<Y1A15R^L*\K2CV=P,;<1H:A'-21"%9S-/W
MAJ20G8RE5'Z"<\_AXY1$47DJTC3*';IF^0=4H%-P'72G=U(X\$OTS8;WE>74
M)9PUO%HY*4M`X;1=[@]=N'N-NTW`E6&$E$X&?T1U=43/6[6#L/8MY:>V],W.
MF+IU954"\AJA<3*;DS:FH1E,D3@@A%2G._=H+*[^(0Y2@7FY1Y1`6NI+N]:&
MF2V@+JG52X9D=>(_\07Y'<J[)S/?N5/?Z\6QJB:2ILJ2E06I:EI3Q$D!(FD;
M_%T0=>-60M$90V7H"]MN9#TVEJZ@FLB1%11,7\'*ID%&<IZ8(F`^!*P<FDHW
M6*.VYB<P;E,`Z.4M;35U&BI:7/*<MBAFGLBK=9:7NFB[_4Z>NB`'V7"`0>ZI
MO8XD[4J3B)83PG`QT]F!7,QU*[@85K4K2Z=!4C8>"NPTJQ)>3_BEQ*2B\4FK
M'N43*C%!')A(FV$J8*\"CS#Q#0I%Z;_[*NVXR\D*GTX;(E]5RZHV.4-+S!\Q
M7"_6N,<'".'N&7%Q3G/;*41F0>.U#96=27JVV)N&V*I`5Q:2TS9O(@DFJ[IR
MH&D=#.*>JB,%0!$C^!E@(N0`$H*`42&^280U'T6]NX:@K&5`<7!@3C+YHN^X
MZMN.C.3VAK]0*"'F*M]1EFM`4>-!V<*DGL.,%UTP<B:U/#7!P6R+>J)Y)8C*
M#3#I\[<"=:YMI4"^#1E=Q9E@*XD"-V"S=NX.7G'P3MU#CS*FV,V"N>92;/4R
M-2)H0/Q`@GB'0F4CUB*_YN:3MK-31\R=+S7I6^24A.?E5*U`N-DC`"8)3@)8
MPWG1<F7=.]/R[=0,4C+NH*^N2TTU;D*!C+N8MR1XV0*`B`"<ZR!0#<0VWURT
MR^IZT/C#S$O.S.[AAQSPMS2N:=!;US\E5#0MKXC/%2$A2O\`+C(#.,.@71L4
MZQ3KJ^\@!9"YM]+VW`FJ^J1UNM,/#0DD"4=&N')_SPMF[M^Z=B7?8RKL3<>&
MN.B0':)VN49O+=4.H3R/7G!#XIJQ:-:4>E6"XFQ6RUTJ6&P2E*5.-\2UR'XS
MMW#&)QI!DS<LG#9TW1>-729VSMHZ(59N[:N"BFX;K(*%,DNBND<2F(8!*<!$
MH@(#J:*_U4EEWTUB1[<(\RL?J&'4OL+<\Q*@1WR0)',8S!&:>F45G\*L::$N
MTMU@NG!.<QK'-[LMQH95D8'2%!351?71HQ[!%/NFF_I*3I^+5`O,7F.P$AN!
MC:ANB'U6V\5E+3`II&'#*>^>,>B_BLL5)KGEUI+4-S''572RAES+C\Y@R0XH
M`3`(VF>V*?F3F.5T,5KT5W8:\<.:(K*B)$\>LH1)4L74T(X,H,'6--K*@4'=
M/5(S$JR"A1-X8F,B8043,4/3%IJT72D")@&6V/B)JK3-?I2\O6>H;/F!PK2K
M(<"3/`GHBX"YS1J^[O1!Q]C*<D7+^_V2R=+881@MCB,FYJMA,*4#5DP?D`JI
MU#4;"&764*&Q57@"8=QU0^O2[;BJBI\*NJ<X0K8D$XDC,X?7'U:^$$LZLJJ;
M5=U[UHLU*JH<492)82>'H$S+/:(VCJ>VCAK>VOZ6&!;!RG%6@J2]M#T36QT5
M%&K:794<TIB'5,_*0Q"G++OJI?O#!S!LY.4X<0W"(7QH4XMMD4D"B4H!1W[(
M](<F+TY<+SK7F25%6H$6YU=,<RA3ZR#+I2@221@(L8PT)%0,?'PL*P:QD1$,
M&,9&QC%(C=E',(Y$C9BS9MTP*F@@V:IE(0@```4`VU8"&D,(#+"0AJ0&&Z/)
M3M6Y45"EU)4MU:E%2U@E2U$DF:CGC$,G7BH"!E,&9>ZAR@TKFREQ*"K>WE0M
MQ\.4B)9W4#*$>MVKO@LBW?(NB*J$((`*S5(X`!B`(0_6C::>TFY@)%:PX.%?
M1Q2X8](?"D_5KYFITTV945PHJA#R,D.@-DCS)X*E+Z8'_J%SCG(*X71XLG<8
MJI;>WSK*D[C7,8.E#%:U-+,*=I%RVA9%,I>1P#@\P\)R&#DW<\>T!!CJ`FL>
MM5._,-5+J2L;#)(/TQ)N4K0TA;-?ZILG=O%OIG*>GD<&O,=4E2D[<$R$QCA%
MB-BP:-&*#=HW(T:L4RH-&J!"HHMFK8O@(-VZ)"E(F@BB0"$(``!2``;<`#4]
M0TE,FQW4#!(&0`RCR*X7'7U*6I2JA:SQJ*E":B<5'&9))F3MC1#7=M@G<TEF
ME*VIHMUST]_&"5OC2[?^+%*5*OZ(-1IPP&]*&)]($4Q6Y>3F';?7,OMMN%H*
MFZF1ET'"'?\`1;L;9_6`PZ;;YI;*R>Z%@Y8]"01UB(1>I+<2IK3]3KI\5_1U
MJZMO34=/V[O8:+ME0BL<E552F?QKZ.<$C%919)@08YJZ.[4\02[I(&Y1$>&H
M7?'WJ;45,6VE.C@43(D9D2&$>H^3=CM.I.4.J+;=KFU;*9=32GS74E38(4F1
M401*76,X/O'K,>]5ZKFM:%KK!#(''R!<0DO)J7$N2^I%:FVSN.]&%K$')$.5
M7HO9<RQ@1V+R;IFW$-&J"[+J*GA4PXV!AB3MPVQ4.K^7^F-/6PW&@U%;[M4A
MU*0VPA4R#M)*L`.J!5ZJ12K9+])ILJFFHFKEZJFH54A3I."'80"9B'3$!3.1
M0@CN4=P$!$!X#MH7?^!=QMC"Q-2WE`'<1M.\8Q/.2LTZ)US4D(2I%I;`!V%3
MJB%IVA2<@>N&ZMVLMTL\\WUF))8\?A5G!4[NH;0R"YQ+!VAOXZ.BE*T4JJJ;
MPHZ(J,ZB:2)>8I/#4:"`;(+FUS92=.W1P+,[94*/#N0N6,]AXLA+*8@E=6F^
M=/+0W^B0#KO3-(ENK`D2_1`X.@#'B1FJ<\B!&U4*LH'7MO<IX`@8<,:/*"._
M$Q/3Z6`1$=MP'D^5V;\.S6[:DC6#BI`NFE!ZLOKC:XJ;=^%.WL`G]$U>WIJE
MC-0*AAG.0E+?'.("G-UF.IB4!$#?X=V?YB@(`<H&90?(.PCMQYO@XZ[6=+IU
M+5+*2$*2#C\T#>8E=2.<AM&4J%H6^W45!4@8J'$3@H;!*6^-EZHMCJXMU.VY
MZC6.D>H-Z<:OS-SX*-15WNC89V<Y:MAY5!L&[]6`8KK*AS`?E9G4/L)FZ(!G
M4%&ZPVU>Z#WU,I1EL*".\.O*4<>1VI+-=45/*K6SR6M+W`J-.ZOPTM4G%LH,
M^[Q&8,AGUQ\CH)/&=28)U$](@5:-G<A+TOP;*&(L46<T^C7)V:IR@5-<2HNN
M0Q@#E,'$.W330P+]@*E)4E;KZRL'I..W:(>?%-2MV;FNS14U0A:FK;2$N),P
M2A$@9],@8&>S]QZJZ,%\[IV6O?3E4RN#EWJZ?U]9Z]-/Q#^?C+:S4VL0KZG*
ML0C$7"S`I&A$&[A("^*)FJ;E`JQ%E03;4;R=*5U0BY$M6EYP%M4B9'<0`93Q
MRG$GU!;Z'XA-,T6H[74,M<P:%A-._3J4E!J6FP0VILG-6P\7",9=,&%?GK18
MJ4[1H1>-M4&RCOG4[06MNK:6LA*@G?2IZ03,G%GJ5V6+0+&-&JQ@47;%$7R@
M$%,J91-SE)U^KK0\D-6MTOUA(X4(2J9QQQ(`P&.?9$&TU\.>NW;@FKUI3BQ:
M;9)4\XZXWWFTXD(`))4H8)R$SB8<+I28EW$QUL[6==WW5Y\B<E*^>W=NP@8R
M:KB#6?\`CK0E+/%$E%D#2,=Z8X<NP3,8B3EX9$HF*B!A<:=H7:5IYVMX0_4.
M<4IF<MQPS@-SNY@6C6>H:>W:226]'6BD%)3#:J4BIQ1F023.71'JZH?3'MIU
M#;2JL7)6-)7VH.-?NK-75*W#TF/?*)&5/1M5@D4AY>@J@<[%71,)CLEC`Y0$
MIRF(K.[7=*BW.=PGRB?HCREK_0-OUK:%4KPX:Y`*D.#!9(!(23N)PBOWT-[)
MW<JK)QE92\M.OX.FNG/6MWZSD:8D14$L;>^Z2T'3C%FX(81;F*R3IYS(1ZA`
MV51`%R[E5*.F.LD-774S%2C&B#6$_P`<L]TNF+!^'ZY_],Y`W.Q+_P!+4]==
M7&EI^\*=$^[//A5MV8Q82ZK&(=6998[QR=J7/U??&R=91MW;/N/$30%_4M/D
M.#FG/2%1(@W4EV)]VJBABI%>H(`H()B8P1C4EL>N%(AQCA\YO$8_;+Y&+@Y+
MZ\I=#ZJX+LF>G+E2KI:F0F$MK$@L`D#B2K''(3E#*8X]9C'.5I<*;RYG5\6\
MA*/8I0]Q:$N?`U%`LW<Y&)^')2],/5(Q1-9E)+)&4(U5$CE,X\A04)R*'X6_
M4;):`KBIM2,#Q"6($B1B<XDFJOA[U;3UPJ-%G^LZ-J#-E]M;0(*L0A0*P04S
MD=F'9`FY(WFG^LA<JAL6L6X.I5<1:0KF&K'(7(68@Y.!IBHD8)V95I2E*C)H
M-5I+G2.L5!+8'#E\H14Q$F[<QU!=Q==U,^:!D'^CX$DX$J&T#$2W'Z(GNC['
M;_AXM-1K?6M2V-=NLN,45O"@M25+3PE;RD3",=Q5!]=3/#.M,@K$6\FL?A;0
MM^,7*H@KCV+1!5%IZ::F4&C=>BTWJZC9L@M(-XUL=H"QTVYG+5,BHE(<QBF;
MQ:55M/3+:D'*5SB&S`)`W9S'5%6\F.95'I74E;3ZI`=TO>V5,5<\4MEPS+@Q
M[Q2HG&67S0V5@^M=CG(P[>C,NUYC%&_=-%^JJ^I*Y-,5)'02\XU$J#E_3DJA
M&NS%CI!<HJ$1=IH*)`;E`5"@50[*FU1;*0^5=WO*K$G%)2HX?=,P",8,:G^'
MC4Z5FY:$X+MIUY7$PXTZWQA),Y+0I22"-X)ABK'Y!6ARDZV:=U;#52A<FWL/
MAK-4=(5=$1<PWB&T\SJMHX79&<R3!D4P`FY()#!\A7G^2(\H[:VZY4-UU$MR
MA<+E*:<)F`H)"PI1(/%(Y$9`P;U1I&Z:*Y%MV;4@;IK^]=BX&>-"EEOA3)7<
M)`QF)3G,&8C[_45O);FPG5$Z>UV;LU,C2-OZ3MY>L\]/NVCYXE'IR<3(1#(Q
MFT6T>2"HN9-^BB4")GV%7?L`=<;_`%=/0ZBI7JNI-.V$*&"2H*E+<#E/Z8TY
M1V:Z:FY-ZCLMC84Y75%33\,W$H`X#Q'B2I0"IA)E_C!H075WZ=M53L)3L)DA
M!/IZI)>*I^'8A2-PDO3I69>H1L4R*NO2I$$5'+YR0A3J'(F43;F,`;CHVQJ>
MRU3Z:5A\.K!!P01+I,P(KFHY*<S*&D765=N*J&G!6HA;0X0!G+S#/LA@.J48
MILGNDL138A0S!$"%(;<PG%C`B8O'O<H![^F=_9E<;<^@$^54*G+<L82^8SB5
M\G%AK0VM7:Q:4U)L[8"21)1+A[@WJD#(2ETP>.;F*%(YBX]5S9JI3$8RK]$)
MJWU5<IAD*(N%$`HO2=2,5T_S[<4'^R#GD'F.T54*`\P@(%[I0LW*E72O>($*
M!Z1BF7;GT16'+?7%ST#JMB]47M5D(J6B>Z_3+[JVW!D<#,#'?%4BU5[,OIG(
M_)PB4/))9K4IB316*KA,4Q4F'->*7NM/9,*W*4-E$5@IRKDI7TP0%+F3%U\T
M<!"JZ.HNYO-6X4']>&D-3^Z1YB$S!SRZ(]Z7ZAY:4^@[%5,N(.@ZB]U5>XU,
M3`2PZ^EHIG*7F(".'BE(RZ(N/07M'J_V:_18_P!7_:)W2>N'[O\`^!][5MTO
MO5^GX=F>>W[(^?55^V4GNLU>/T?]KIW]D;G4_DTKY1Y7+>?^1_0'7G'[G_6_
MV?FUU?\`1^[M\7AB*TWNJ3Q^Z/A\?\OYMT,YC;[-Q]A7GDG]GKV=]YMW?W]^
MM_V-,K3Z7W/&?3\,2O7O[DOW_A1[WU\MG_K_``PX-R_4JH_4#Z&Z]I'J1\R;
MUD_8/ROZ&^B%?Z/_`!]GK>'^/^,#M._NK/O/`?;>/,>'\V[HG`<XJ>M,M_\`
M/[O!]F#UN[JGFGQ_VM"K?ZH]CM]/Q_PW]L6=K7]O_P#U7A_YGI9_5NB05M_N
M?FN_^+V?C=S_`"[=$7_71X,^WLZ8IA'H-^'U#X<MOTQ[E_F5NSN&[/ZINS^E
MKHYZ:NHPX&>WLS[.F!1L_P"V?)+[.GKA1WLF]L/J8E]H_P#O9_T?]U;:VJ?2
M;SRV^*!K/[FOP>)?ARRV_F@I%NZ?N]P_SG9^+_J_'MK=KT8<+])W/MR[(C_R
MV\VA/L(?-H_:H]9.U/RC]%_-J%7_`-P/:;?%]ORSBUM%?M:/[BS/M?;_`,OY
M_M@I+.^SJ`]EGT='V.^S[NI>3?H_BT=T]Z"O2S^YEV1$M6?OROW';[[U>WIA
MTB_1A[G8KV?UQ_#\6C@\/SQ$*+PGT_O?Y/$<^F`*RV[\/]AOYW_VI\W]SR?]
M%J/O>N?8?[GB_ANBX>7W@5_<N:O:^EL\/1#RXW^J*?V:NXU^SGZK=H?/?I/R
M?@UO3>I_Q?\`9@-K#W*?WCU#[W/+9&TW2\PC?8-]!4]K7F7SQ/*OV+\O])KM
M5^HCVVWU/%L\/V]D#].>W/[MXS[7P_S?FALF'F,=]C3Z<R\L\R^D)^7_`+?^
MK_I=M#'?<M^R\6SQ91)JCV;G]S^F?'Z?\_Y=\/377G5">SKSW_O7S[N)>H/]
MX?\`9VT:?]5OP9C/[.G=VQ`K![>N][Z:/2]';ZW1N[8<\.X/W`[_`'N^;O\`
M]/X].5>ZV;.KY;H$U7KNY>B/EU0+4#]I"N/LX>41GDGM[[\!ZX_N_P#5_A]%
CT,3^X*]#,9>+,>+[.R)W5_V!2?NGB7XO:>%7I_F_%VQ__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
